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Background: Drug-induced torsades de pointes (TdP) is a lethal side effects antiarrhythmic drugs. Reverse-use dependant property of drug is 
responsible for bradycardia associated QT prolongation and TdP. The blockade of rapidly activating delayed rectifier potassium current (IKr) is 
believed to be a principle mechanism responsible for reverse-use dependant properties of class-III antiarrhythmic drugs. We tested the hypothesis 
that the late sodium current (INa-L) also contribute to reverse-use dependence.
Methods: Arterially perfused rabbit left ventricular wedge was used. Action potentials from endocardium were recorded simultaneously with a 
transmural ECG. Action potential duration, QT interval, Tp-e interval (interval from peak to end of T wave on ECG) were calculated at various basic 
cycle length (BCL) at baseline and after drug infusion. Effects of ATX-II (an INa-L enhancer), sotalol (IKr blocker), clarithromycin (a weak IKr blocker) 
and ranolazine (an INa-L blocker) on rate-dependent changes in QT, Tp-e intervals and arrhythmic events were tested, either alone or in combination. 
Rate-dependent QT slope (QT-BCL), Tp-e slope (Tp-e-BCL) and TdP score (an index of TdP liability) were calculated.
Results: ATX-II (30 nM) and sotalol (300 μM) caused a significant increase in QT and Tp-e intervals, steeper QT-BCL and Tp-e-BCL slopes (i.e. 
reverse-use dependence), and TdP scores (n=5,p<0.05). Addition of 15 μM ranolazine to ATX-II or sotalol significantly decreased steepness of QT-
BCL, Tp-e-BCL slopes and reduced TdP score (decreased reverse-use dependence) (n=5, p<0.05). In contrast, clarithromycin at 100 μM moderately 
prolonged QT and Tp-e without causing R-on-T extrasystole or TdP, but addition of ATX-II (1 nM) to 100 μM clarithromycin markedly increase the 
steepness of the QT-BCL and Tp-e-BCL slopes and further increased TdP score (potentiating of reverse use dependence) (n=5, p<0.05).
Conclusion: Modulation of INa,L can significantly alter drug’s reverse-use dependence effects on QT as well as Tp-e, and resultant TdP liability. This 
results indicates that inhibition of INa,L can markedly reduce the TdP risk of QT prolonging agents.
